A Comparative Study of The Effect of Selectivity of COX-2 Inhibition (Meloxicam & Celecoxib) on Some Cardiovascular RiskMarkers in Patients With Rheumatoid Arthritis

Background: Prostaglandin G/H Synthases (Cyclooxygenases) are enzymes that catalyze the conversion of arachidonic acid to a series of compounds ending in prostaglandins, endogenous compounds triggering many biological & physiological events in many systems including circulatory & renal syst...

Full description

Bibliographic Details
Main Authors: Ali Mohammed Hadi, Shatha Hussein Ali
Format: Article
Language:English
Published: College of Pharmacy / Mustansiriyah University 2010-06-01
Series:Al-Mustansiriyah Journal of Pharmaceutical Sciences
Online Access:https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/321
_version_ 1797223895744380928
author Ali Mohammed Hadi
Shatha Hussein Ali
author_facet Ali Mohammed Hadi
Shatha Hussein Ali
author_sort Ali Mohammed Hadi
collection DOAJ
description Background: Prostaglandin G/H Synthases (Cyclooxygenases) are enzymes that catalyze the conversion of arachidonic acid to a series of compounds ending in prostaglandins, endogenous compounds triggering many biological & physiological events in many systems including circulatory & renal systems. The normal balance between Cox-1 derived thromboxane A2 (TXA2) which acts as a platelet activator enhancing thrombosis, & the antithrombotic cardioprotective effects of prostacyclin (PGI2) which is produced through Cox-2 activity. Thus inhibition of Cox-2 derived PGI2 will exaggerate the cardiovascular effects of TXA2. Cyclooxygenase - 2 (Cox-2) inhibitors have different odds on cardiovascular risk factors through selectivity to that enzyme that could play a role in their pharmacological action. Objective: Our study includes a comparison between the effects of the purely cox-2 selective inhibitor (Celecoxib), and the relatively Cox-2 selective inhibitor (Meloxicam) on some cardiovascular risk markers in patients suffering from rheumatoid arthritis. Materials &Methods: Thirty –six patients were selected as having rheumatoid arthritis (RA) with age range of 30-60 years (48±9.72), in addition to a group of normal subjects (12) were included as a control group Specific biochemical investigations based on measuring highly sensitive kit for serum C – reactive protein (hs-CRP), serum creatine kinase( CK), serum aspartate aminotransferase(AST), serum urea, serum creatinine, and serum lipid profile. The patients were treated with celecoxib 400mg/day or with meloxicam 15mg/day for 3 months period. Results: Both drugs were able to reduce (significantly) the highly sensitive Creactive protein and increase serum total cholesterol, Low Density Lipoprotein /High Density Lipoprotein (LDL/HDL) ratio as compared pretreatment values. Both drugs have nearly the same effects on renal function presented by decreasing glomerular filtration rate (GFR) as indicated by elevating serum urea levels. Conclusion: The selectivity of COX2 inhibition is not the major character that could be correlated with cardiovascular events related to their administration. Since, meloxicam could aggravate some cardiovascular risk factors more than celecoxib does, as presented a significant increment in serum CK activity.
first_indexed 2024-04-24T13:44:30Z
format Article
id doaj.art-f198a4aa9c834c9a95c5903909ae6bfe
institution Directory Open Access Journal
issn 1815-0993
2959-183X
language English
last_indexed 2024-04-24T13:44:30Z
publishDate 2010-06-01
publisher College of Pharmacy / Mustansiriyah University
record_format Article
series Al-Mustansiriyah Journal of Pharmaceutical Sciences
spelling doaj.art-f198a4aa9c834c9a95c5903909ae6bfe2024-04-04T06:59:09ZengCollege of Pharmacy / Mustansiriyah UniversityAl-Mustansiriyah Journal of Pharmaceutical Sciences1815-09932959-183X2010-06-017110.32947/ajps.v7i1.321A Comparative Study of The Effect of Selectivity of COX-2 Inhibition (Meloxicam & Celecoxib) on Some Cardiovascular RiskMarkers in Patients With Rheumatoid ArthritisAli Mohammed Hadi0Shatha Hussein Ali1Clinical Biochemistry/College of Pharmacy, University of Basrha.Clinical Biochemistry/College of Pharmacy, University of Baghdad Background: Prostaglandin G/H Synthases (Cyclooxygenases) are enzymes that catalyze the conversion of arachidonic acid to a series of compounds ending in prostaglandins, endogenous compounds triggering many biological & physiological events in many systems including circulatory & renal systems. The normal balance between Cox-1 derived thromboxane A2 (TXA2) which acts as a platelet activator enhancing thrombosis, & the antithrombotic cardioprotective effects of prostacyclin (PGI2) which is produced through Cox-2 activity. Thus inhibition of Cox-2 derived PGI2 will exaggerate the cardiovascular effects of TXA2. Cyclooxygenase - 2 (Cox-2) inhibitors have different odds on cardiovascular risk factors through selectivity to that enzyme that could play a role in their pharmacological action. Objective: Our study includes a comparison between the effects of the purely cox-2 selective inhibitor (Celecoxib), and the relatively Cox-2 selective inhibitor (Meloxicam) on some cardiovascular risk markers in patients suffering from rheumatoid arthritis. Materials &Methods: Thirty –six patients were selected as having rheumatoid arthritis (RA) with age range of 30-60 years (48±9.72), in addition to a group of normal subjects (12) were included as a control group Specific biochemical investigations based on measuring highly sensitive kit for serum C – reactive protein (hs-CRP), serum creatine kinase( CK), serum aspartate aminotransferase(AST), serum urea, serum creatinine, and serum lipid profile. The patients were treated with celecoxib 400mg/day or with meloxicam 15mg/day for 3 months period. Results: Both drugs were able to reduce (significantly) the highly sensitive Creactive protein and increase serum total cholesterol, Low Density Lipoprotein /High Density Lipoprotein (LDL/HDL) ratio as compared pretreatment values. Both drugs have nearly the same effects on renal function presented by decreasing glomerular filtration rate (GFR) as indicated by elevating serum urea levels. Conclusion: The selectivity of COX2 inhibition is not the major character that could be correlated with cardiovascular events related to their administration. Since, meloxicam could aggravate some cardiovascular risk factors more than celecoxib does, as presented a significant increment in serum CK activity. https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/321
spellingShingle Ali Mohammed Hadi
Shatha Hussein Ali
A Comparative Study of The Effect of Selectivity of COX-2 Inhibition (Meloxicam & Celecoxib) on Some Cardiovascular RiskMarkers in Patients With Rheumatoid Arthritis
Al-Mustansiriyah Journal of Pharmaceutical Sciences
title A Comparative Study of The Effect of Selectivity of COX-2 Inhibition (Meloxicam & Celecoxib) on Some Cardiovascular RiskMarkers in Patients With Rheumatoid Arthritis
title_full A Comparative Study of The Effect of Selectivity of COX-2 Inhibition (Meloxicam & Celecoxib) on Some Cardiovascular RiskMarkers in Patients With Rheumatoid Arthritis
title_fullStr A Comparative Study of The Effect of Selectivity of COX-2 Inhibition (Meloxicam & Celecoxib) on Some Cardiovascular RiskMarkers in Patients With Rheumatoid Arthritis
title_full_unstemmed A Comparative Study of The Effect of Selectivity of COX-2 Inhibition (Meloxicam & Celecoxib) on Some Cardiovascular RiskMarkers in Patients With Rheumatoid Arthritis
title_short A Comparative Study of The Effect of Selectivity of COX-2 Inhibition (Meloxicam & Celecoxib) on Some Cardiovascular RiskMarkers in Patients With Rheumatoid Arthritis
title_sort comparative study of the effect of selectivity of cox 2 inhibition meloxicam celecoxib on some cardiovascular riskmarkers in patients with rheumatoid arthritis
url https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/321
work_keys_str_mv AT alimohammedhadi acomparativestudyoftheeffectofselectivityofcox2inhibitionmeloxicamcelecoxibonsomecardiovascularriskmarkersinpatientswithrheumatoidarthritis
AT shathahusseinali acomparativestudyoftheeffectofselectivityofcox2inhibitionmeloxicamcelecoxibonsomecardiovascularriskmarkersinpatientswithrheumatoidarthritis
AT alimohammedhadi comparativestudyoftheeffectofselectivityofcox2inhibitionmeloxicamcelecoxibonsomecardiovascularriskmarkersinpatientswithrheumatoidarthritis
AT shathahusseinali comparativestudyoftheeffectofselectivityofcox2inhibitionmeloxicamcelecoxibonsomecardiovascularriskmarkersinpatientswithrheumatoidarthritis